MORGAN STANLEY PLC/PUT/REVVITY/75/0.1/20.09.24

MORGAN STANLEY PLC/PUT/REVVITY/75/0.1/20.09.24 Share Price

DE000ME2W498

Delayed Börse Stuttgart 11:34:57 26/06/2024 BST
0.167 ^EUR	-1.18%

Current month	+48.25%
1 month	+106.10%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart REVVITY, INC.

Chart MORGAN STANLEY PLC/PUT/REVVITY/75/0.1/20.09.24

Latest news about REVVITY, INC.

Bionano Genomics Says Revvity to Commercialize VIA Software	06-20	MT
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research	06-20	AQ
Bionano Genomics, Inc. Announces Software Marketing Agreement with Revvity, Inc. for Newborn Sequencing Research	06-20	CI
GenKOre Announces Strategic Collaboration with Revvity to Develop Innovative Gene Therapy Treatments	06-18	CI

More news

Quotes 5-day view

Date	Price	Change
26/06/24	0.167	-1.18%
25/06/24	0.169	+1.20%
24/06/24	0.167	+4.38%
21/06/24	0.16	-3.61%
20/06/24	0.166	+27.69%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 11:34 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	REVVITY, INC.
Issuer	Morgan Stanley
WKN	ME2W49
ISIN	DE000ME2W498
Date issued	01/11/2023
Strike	75 $
Maturity	20/09/2024 (87 Days)
Parity	10 : 1
Emission price	0.7 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.94 €
Lowest since issue	0.063 €
Delta	-0.11x
Omega	5.407
Premium	30.41x
Gearing	47.88x
Moneyness	0.7167
Difference Strike	-29.64 $
Difference Strike %	-39.52%
Spread	0.075 €
Spread %	30.99%
Theoretical value	0.2045
Implied Volatility	67.67 %
Total Loss Probability	81.21 %
Intrinsic value	0.000000
Present value	0.2045
Break even	72.82 €
Theta	-0.02x
Vega	0.01x
Rho	-0x

Company Profile

Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows: - medical diagnosis equipment (61%); - analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc. Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).

Sector

More about the company

Ratings for Revvity, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Revvity, Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

104.6 USD

Average target price

124.1 USD

Spread / Average Target

+18.60%

Consensus